Pharmaceuticals, Biotechnology and Life Sciences
FDA has reported that the federal judge ordered a New Jersey company that sold injectable skin whitening and other beauty products to stop selling and recall some of its products because they are unapproved new drugs that may be unsafe, putting consumers at risk.
Novartis has enterned in new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers.
Allergy Therapeutics, a pharmaceutical group specialising in allergy vaccines, has announced that the fully-funded Phase II clinical trial investigating the dosing of PQ Grass has received clinical trial application (CTA) approval.
Sandoz, a Novartis division has reported new data on its proposed biosimilar adalimumab.
Basilea Pharmaceutica’s Basilea Pharmaceutica International Ltd. has entered into a distribution agreement with Cardiome Pharma Corp. for Basilea’s antibiotic Zevtera/Mabelio (ceftobiprole) in Europe (excluding Nordic countries) and Israel.
Rituxan is used to treat blood cancers including non-Hodgkin’s lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis.
Allergan has reached a settlement regarding its litigation with Famy Care Limited relating to certain Allergan’s United States Patent covering Restasis (Cyclosporine Ophthalmic Emulsion) 0.05%.
Novartis has revealed primary data from CANTOS, a Phase III study evaluating quarterly injections of ACZ885 (canakinumab) in people with a prior heart attack and inflammatory atherosclerosis as measured by high-sensitivity C-reactive protein (hsCRP) levels of >=2mg/L, a known marker of inflammation.
The U.S. Food and Drug Administration (FDA) has approved a new indication for Novo Nordisk’s Victoza (liraglutide) to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes and established CV disease.
Otsuka Pharmaceutical and Mylan N.V. have entered into a license agreement between their respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan Pharmaceuticals Private Limited (Mylan), to commercialize delamanid for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in low- and middle-income countries.